David B. Ridley

893 total citations
39 papers, 546 citations indexed

About

David B. Ridley is a scholar working on Economics and Econometrics, Pharmacology and General Health Professions. According to data from OpenAlex, David B. Ridley has authored 39 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Economics and Econometrics, 8 papers in Pharmacology and 6 papers in General Health Professions. Recurrent topics in David B. Ridley's work include Pharmaceutical Economics and Policy (23 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Healthcare Policy and Management (9 papers). David B. Ridley is often cited by papers focused on Pharmaceutical Economics and Policy (23 papers), Health Systems, Economic Evaluations, Quality of Life (10 papers) and Healthcare Policy and Management (9 papers). David B. Ridley collaborates with scholars based in United States, United Kingdom and Switzerland. David B. Ridley's co-authors include Henry G. Grabowski, Margaret Kyle, Kevin A. Schulman, Stéphane A. Régnier, Eli Liebman, Kirsten Axelsen, Peter Arcidiacono, Paul B. Ellickson, Ali Yürükoğlu and Xiaoshu Bei and has published in prestigious journals such as The Lancet, Nature Reviews Drug Discovery and The Review of Economics and Statistics.

In The Last Decade

David B. Ridley

36 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David B. Ridley United States	13	411	94	79	76	61	39	546
Amber Jessup United States	9	277 0.7×	162 1.7×	22 0.3×	16 0.2×	61 1.0×	14	719
Szymon Jarosławski France	9	127 0.3×	48 0.5×	12 0.2×	15 0.2×	33 0.5×	23	335
Annika Herr Germany	12	303 0.7×	36 0.4×	17 0.2×	23 0.3×	7 0.1×	29	486
Christoph Schwierz Belgium	10	249 0.6×	18 0.2×	40 0.5×	13 0.2×	20 0.3×	22	368
Matthew Herder Canada	11	139 0.3×	93 1.0×	48 0.6×	26 0.3×	9 0.1×	55	346
Stuart Hogarth United Kingdom	12	54 0.1×	178 1.9×	42 0.5×	42 0.6×	6 0.1×	28	563
Stephen M. Sammut United States	8	118 0.3×	189 2.0×	15 0.2×	46 0.6×	8 0.1×	14	373
Roberto Rodríguez‐Ibeas Spain	11	207 0.5×	23 0.2×	31 0.4×	4 0.1×	19 0.3×	29	309
Hannah Kettler United States	11	168 0.4×	105 1.1×	10 0.1×	78 1.0×	8 0.1×	20	391
Maurice Cassier France	11	97 0.2×	63 0.7×	16 0.2×	68 0.9×	3 0.0×	49	332

Countries citing papers authored by David B. Ridley

Since Specialization

Citations

This map shows the geographic impact of David B. Ridley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Ridley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Ridley more than expected).

Fields of papers citing papers by David B. Ridley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Ridley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Ridley. The network helps show where David B. Ridley may publish in the future.

Co-authorship network of co-authors of David B. Ridley

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Ridley. A scholar is included among the top collaborators of David B. Ridley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Ridley. David B. Ridley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ridley, David B., et al.. (2024). European priority review vouchers for neglected disease product development. BMJ Global Health. 9(1). e013686–e013686. 3 indexed citations

Liebman, Eli, et al.. (2023). Consequences of a shortage and rationing: Evidence from a pediatric vaccine. Journal of Health Economics. 92. 102819–102819. 3 indexed citations

Ridley, David B., et al.. (2023). FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels. Health Affairs. 42(12). 1758–1766. 2 indexed citations

Ridley, David B., et al.. (2021). US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access. Health Affairs. 40(8). 1243–1251. 6 indexed citations

Ridley, David B., et al.. (2019). Does Medicare Reimbursement Drive Up Drug Launch Prices?. The Review of Economics and Statistics. 102(5). 980–993. 7 indexed citations

Ridley, David B., et al.. (2017). A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases. Health Affairs. 36(8). 1461–1468. 7 indexed citations

Ridley, David B. & Su Zhang. (2016). Regulation of price increases. International Journal of Industrial Organization. 50. 186–213. 2 indexed citations

Ridley, David B., Xiaoshu Bei, & Eli Liebman. (2016). No Shot: US Vaccine Prices And Shortages. Health Affairs. 35(2). 235–241. 13 indexed citations

Ridley, David B. & Stéphane A. Régnier. (2016). The Commercial Market For Priority Review Vouchers. Health Affairs. 35(5). 776–783. 29 indexed citations

10.

Régnier, Stéphane A. & David B. Ridley. (2015). Forecasting market share in the US pharmaceutical market. Nature Reviews Drug Discovery. 14(9). 594–595. 9 indexed citations

11.

Ridley, David B.. (2013). PAYMENTS, PROMOTION, AND THE PURPLE PILL. Health Economics. 24(1). 86–103. 4 indexed citations

12.

Ridley, David B., et al.. (2010). Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. The Lancet. 376(9744). 922–927. 22 indexed citations

13.

Ridley, David B., et al.. (2007). PCV48 IMPACT OF MEDICAID PREFERRED DRUG LISTS ON THERAPEUTIC ADHERENCE. Value in Health. 10(3). A51–A51. 4 indexed citations

14.

Kyle, Margaret & David B. Ridley. (2007). Would Greater Transparency And Uniformity Of Health Care Prices Benefit Poor Patients?. Health Affairs. 26(5). 1384–1391. 42 indexed citations

15.

Ridley, David B. & Kirsten Axelsen. (2006). Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence. PharmacoEconomics. 24(S3). 65–78. 21 indexed citations

16.

Ridley, David B., Judith M. Kramer, Hugh H. Tilson, Henry G. Grabowski, & Kevin A. Schulman. (2006). Spending On Postapproval Drug Safety. Health Affairs. 25(2). 429–436. 10 indexed citations

17.

Ridley, David B., et al.. (2006). Developing Drugs For Developing Countries. Health Affairs. 25(2). 313–324. 126 indexed citations

18.

Ridley, David B.. (2005). Price Differentiation and Transparency in the Global Pharmaceutical Marketplace. PharmacoEconomics. 23(7). 651–658. 32 indexed citations

19.

Ridley, David B. & Kevin A. Schulman. (2004). Differential Pricing of Pharmaceuticals in the Internet Age. Journal of Ambulatory Care Management. 27(3). 210–214. 2 indexed citations

20.

Ridley, David B., et al.. (1996). Dermatological Problems in the Athlete. Journal of Orthopaedic and Sports Physical Therapy. 23(6). 388–402. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact